Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZ-629 Safety, PK/PD, and Food Effect in Healthy Subjects and T2D Patients
NCT06829563Phase 1Recruiting
- Sponsor
- Rezubio Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RZ-629 in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Rezubio Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started Jan 2025; status: recruiting.
02
Drugs
RZ-629
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06829563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829563.